Adherence and persistence are important considerations when it comes to your patient's dosing regimen

There are many reasons patients and providers choose to start or discontinue treatment, from adverse events to patient preference.

In the OCREVUS RMS clinical trials, the percentage of patients who completed the clinical trials at year 2 were 4:


Adherence and persistence in the OCREVUS 1-year analysis 43
  • OCREVUS was studied using real-world claims data in a 1-year analysis assessing 1,121 OCREVUS patients from March 28, 2017 to June 2018
Chart defining aherence and persistence. 92% of patients remained adherent on OCREVUS, while 8% did not. Another 92% of patients remained persistent on OCREVUS, while 8% discontinued treatment.
Limitations of OCREVUS 1-year real-world analysis
  • Claims data have inherent limitations:
    • Limited clinical information available may result in residual confounding (eg, MS subtype, line of therapy)
    • Lack of data on reason for discontinuation
    • Data may not be generalized to all patients, including those without insurance
  • A subset of OCREVUS patients were identified by algorithm; a sensitivity analysis was performed on only confirmed OCREVUS patients and showed similar results

Dosing and administration

Visit the OCREVUS dosing schedule for your patients.

Request information

Speak to an OCREVUS Representative to learn more about OCREVUS.